Physician profile

Peter Saccone

Pulmonary Disease · Linwood, NJ

NPI 1295066181

$149,382.74

in general payments reported to CMS, 2019-2025

43 companies · $11K in 2025

The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$58,776.50
Food and Beverage$9,010.70
Travel and Lodging$935.97
Education$271.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $65,273.57 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals Lp $55,272.55 2019-2025 Breztri, Tezspire, Airsupra
Mylan Specialty L.P. $16,198.94 2019-2024 Yupelri, Yupelri
Viatris Specialty LLC $3,833.67 2025 Yupelri
Genzyme Corporation $1,066.37 2019-2025
Regeneron Healthcare Solutions, INC. $775.28 2019-2025 Dupixent
Boehringer Ingelheim Pharmaceuticals, INC. $758.70 2019-2025 Spiriva Respimat, Ofev, Jascayd
Philips North America LLC $707.24 2019-2025 (Ak6) Vest Therapy, Vest Therapy Und, Incourage Airway Clearance Therapy
Viiv Healthcare Company $600.00 2019
Amgen INC. $521.72 2021-2025 Tezspire
Harmony Biosciences LLC $506.56 2021-2025 Wakix
Jazz Pharmaceuticals INC. $407.03 2019-2025
Novartis Pharmaceuticals Corporation $405.96 2019-2025
Genentech USA, INC. $380.15 2019-2025 Xolair
Grifols USA, LLC $332.51 2019-2025 Prolastin-C Liquid
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Axsome Therapeutics, INC. $306.41 2023-2025 Sunosi
Insmed, INC. $213.30 2019-2024 Arikayce
Mallinckrodt Hospital Products INC. $187.47 2021-2025 Acthar
Advanced Respiratory, INC $174.93 2019-2021
Teva Pharmaceuticals USA, INC. $151.91 2019-2022
Sanofi-Aventis U.S. LLC $134.98 2024-2025
Avadel Cns Pharmaceuticals, LLC $130.42 2024-2025 Lumryz
Verona Pharma, INC. $121.37 2025 Ohtuvayre
Sunovion Pharmaceuticals INC. $120.71 2019-2021
Takeda Pharmaceuticals U.S.A., INC. $112.31 2020-2025 Aralast
Electromed, INC. $96.90 2019-2025 Smartvest
Baxter Healthcare $95.53 2022-2025
Ani Pharmaceuticals, INC. $87.20 2023-2025 Purified Cortrophin Gel
Inspire Medical Systems, INC. $80.01 2023-2025 Inspire
Covis Pharma Gmbh $40.59 2022-2023
Idorsia Pharmaceuticals US INC $33.62 2024 Quviviq
Resmed Corp $31.22 2023
Ucb, INC. $29.41 2021
Merck Sharp & Dohme LLC $29.31 2023-2024 Winrevair
Actelion Pharmaceuticals US, INC. $27.50 2021-2023 Uptravi, Opsumit
Shire North American Group INC $26.98 2019
Phadia US INC. $20.29 2023 Immunocap
Circassia INC. $17.99 2019
Inogen, INC. $17.97 2025
Pulmonx Corporation $16.84 2024 Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter
United Therapeutics Corporation $14.71 2023 Tyvaso
Horizon Therapeutics Plc $11.36 2019
Mallinckrodt Enterprises LLC $11.25 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Saccone

$149,382.74

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $11K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/571241/peter-saccone

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.